ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för dabrafenib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

25 träffar

Bibliografisk träff 2013-12-01

Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.

Anforth R, Blumetti TC, Clements A, Kefford R, Long GV, Fernandez-Peñas P.

Br J Dermatol · research support, non-u.s. gov't; journal article · DOI 10.1111/bjd.12519

Bibliografisk träff 2013-08-01

Dabrafenib: first global approval.

Ballantyne AD, Garnock-Jones KP.

Drugs · journal article · DOI 10.1007/s40265-013-0095-2

Bibliografisk träff 2013-07-19

Paradoxical oncogenesis: are all BRAF inhibitors equal?

Menzies AM, Kefford RF, Long GV.

Pigment Cell Melanoma Res · journal article · DOI 10.1111/pcmr.12132

Bibliografisk träff 2013-07-12

Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors.

Denton CL, Minthorn E, Carson SW, Young GC, Richards-Peterson LE, Botbyl J, Han C, Morrison RA, Blackman SC, Ouellet D.

J Clin Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1002/jcph.127

Bibliografisk träff 2013-07-05

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

Nathanson KL, Martin AM, Wubbenhorst B, Greshock J, Letrero R, D'Andrea K, O'Day S, Infante JR, Falchook GS, Arkenau HT, Millward M, Brown MP, Pavlick A, Davies MA, Ma B, Gagnon R, Curtis M, Lebowitz PF, Kefford R, Long GV.

Clin Cancer Res · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-13-0827

Bibliografisk träff 2013-07-03

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.

King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, Smitheman KN, Erhardt JA, Hughes-Earle A, Kane-Carson LS, Sinnamon RH, Qi H, Rheault TR, Uehling DE, Laquerre SG.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0067583

Bibliografisk träff 2013-06-01

Dermatological adverse events from BRAF inhibitors: a growing problem.

Belum VR, Fischer A, Choi JN, Lacouture ME.

Curr Oncol Rep · review; journal article · DOI 10.1007/s11912-013-0308-6

Bibliografisk träff 2013-06-01

Dabrafenib in the treatment of advanced melanoma.

Medina T, Amaria MN, Jimeno A.

Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2013.49.6.1968669

Bibliografisk träff 2013-05-24

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.

Luke JJ, Hodi FS.

Oncologist · research support, non-u.s. gov't; research-article; review; journal article · DOI 10.1634/theoncologist.2012-0391

Bibliografisk träff 2013-05-08

Companion biomarkers: paving the pathway to personalized treatment for cancer.

Duffy MJ, Crown J.

Clin Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1373/clinchem.2012.200477

Bibliografisk träff 2013-04-29

Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.

Gibney GT, Zager JS.

Expert Opin Drug Metab Toxicol · review; journal article · DOI 10.1517/17425255.2013.794220

Bibliografisk träff 2013-04-25

B-Raf and the inhibitors: from bench to bedside.

Huang T, Karsy M, Zhuge J, Zhong M, Liu D.

J Hematol Oncol · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1186/1756-8722-6-30

Bibliografisk träff 2013-04-22

Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors.

Ouellet D, Grossmann KF, Limentani G, Nebot N, Lan K, Knowles L, Gordon MS, Sharma S, Infante JR, Lorusso PM, Pande G, Krachey EC, Blackman SC, Carson SW.

J Pharm Sci · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/jps.23519

Bibliografisk träff 2013-03-19

Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.

Klinac D, Gray ES, Millward M, Ziman M.

Front Oncol · review-article; journal article · DOI 10.3389/fonc.2013.00054

Bibliografisk träff 2013-03-01

Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib.

Falchook GS, Rady P, Hymes S, Nguyen HP, Tyring SK, Prieto VG, Hong DS, Kurzrock R.

JAMA Dermatol · research support, non-u.s. gov't; research-article; journal article; case reports · DOI 10.1001/jamadermatol.2013.2023

Bibliografisk träff 2013-02-27

Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma.

Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci · journal article · DOI 10.1016/j.jchromb.2013.02.025

Bibliografisk träff 2013-02-12

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.

Wilmott JS, Menzies AM, Haydu LE, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA, Long GV.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/bjc.2013.29

Bibliografisk träff 2013-02-01

BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.

Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R.

Oncotarget · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; case reports; research support, n.i.h., extramural · DOI 10.18632/oncotarget.864

Bibliografisk träff 2013-01-14

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.

Gentilcore G, Madonna G, Mozzillo N, Ribas A, Cossu A, Palmieri G, Ascierto PA.

BMC Cancer · other; research support, non-u.s. gov't; journal article · DOI 10.1186/1471-2407-13-17

Bibliografisk träff 2013-01-02

Resistance to BRAF-targeted therapy in melanoma.

Sullivan RJ, Flaherty KT.

Eur J Cancer · review; journal article · DOI 10.1016/j.ejca.2012.11.019

Bibliografisk träff 2013-01-01

Cutaneous toxicities of RAF inhibitors.

Anforth R, Fernandez-Peñas P, Long GV.

Lancet Oncol · review; journal article · DOI 10.1016/s1470-2045(12)70413-8

Bibliografisk träff 2013-01-01

Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation.

Chapman PB.

Am Soc Clin Oncol Educ Book · research support, non-u.s. gov't; review; journal article · DOI 10.14694/edbook_am.2013.33.e80

Bibliografisk träff 2012-12-17

Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.

Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF.

J Pharmacol Exp Ther · research-article; journal article; research support, n.i.h., extramural · DOI 10.1124/jpet.112.201475

Bibliografisk träff 2012-12-10

BRAF inhibitor activity in V600R metastatic melanoma.

Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV.

Eur J Cancer · journal article; case reports · DOI 10.1016/j.ejca.2012.11.004

Bibliografisk träff 2012-09-14

(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.

Carlino MS, Saunders CA, Haydu LE, Menzies AM, Martin Curtis C, Lebowitz PF, Kefford RF, Long GV.

Eur J Cancer · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1016/j.ejca.2012.08.018